InTORduction
B (as in billion) cells
Novel therapies, new chapters
SDMT revisited
The year 2019 saw important changes in how multiple sclerosis is being managed in an a increasingly complex therapeutic landscape (reviewed in Cree et al. Curr Opin Neurol 2019;32:365-377). The tectonics of that landscape are also shifting as new drugs are approved, generic formulations become available and the hothouse regulatory environment cools. Read More
A case of progressive multifocal leukoencephalopathy (PML) has been reported in a previously untreated MS patient who received ocrelizumab. The case was first reported on a blog posted by Dr. Gavin Giovannoni, Barts and The London School of Medicine and Dentistry. Details of the case were confirmed in an email from Roche to NeuroSens. Read More
Click here to take the new sequencing survey
Cliquez ici pour remplir le nouveau sondage sur les séquences thérapeutiques
Two years ago, NeuroSens concluded its eight-part series on sequencing disease-modifying therapies (DMT) in multiple sclerosis. Expert commentaries were provided by Canadian MS specialists, including Drs. Mark Freedman, Ottawa; Michael Yeung, Calgary; Paul Giacomini, Montreal; Daniel Selchen, Toronto; Jiwon Oh, Toronto; and Marc Girard, Montreal. Each article was accompanied by a reader survey to identify clinicians’ goals of therapy, DMT use and perceptions about the relative benefits and risks of different treatment sequences. Read More
Recent positive trials in primary- and secondary-progressive MS (ORATORIO, EXPAND) have fuelled interest in the etiology, pathophysiology and treatment of progressive MS (reviewed in Secondary-progressive MS: conceptual and practical challenges, NeuroSens, April 17, 2019; and Progressive MS trials – design and interpretation, NeuroSens, September 4, 2019). In Part 3 of this series, we summarize some emerging concepts in PMS and new trial data in SPMS. Read More